The process that rebranded Albany Molecular Research Inc. as "AMRI" began about a year ago with a transtional logo. The 16-year-old Albany-based drug-discovery company had just purchased a company ...

NEW YORK, June 9, 2017 /PRNewswire/ -- The proposed acquisition of Albany Molecular Research Inc. ("AMRI" or the "Company") (NASDAQ: AMRI) by affiliates Carlyle Group LP and GTCR LLC (the ...

William Marth, president and CEO of Albany Molecular Research Inc. Marth assumed those roles at the start of 2014, succeeding co-founder Tom D'Ambra (who is now AMRI's chairman). AMRI; Albany ...

WESTPORT, Conn.--(BUSINESS WIRE)--ViralClear Pharmaceuticals, Inc. (ViralClear), supported by Albany Molecular Research Inc., (AMRI), a leading global contract ...

Albany Molecular Research Inc. said Tuesday it has ... The deal has been approved by AMRI's board and must now be approved by shareholders. The deal will be financed with a mixture of debt and ...

The sale of Albany Molecular Research Inc. in a $922 million ... Advertisement Article continues below this ad At the time, AMRI's shares were trading for roughly $14.50. Fifteen months later ...

ALBANY, N.Y.--(BUSINESS WIRE)--Albany Molecular Research, Inc., (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that its ...

ALBANY, N.Y., June 6, 2017 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences ...

An Albany Molecular Research shareholder claims the ... "The merger is a self-interested transaction in which AMRI's chief executive officer, William S. Marth, and its board decided to sell ...

About AMRI AMRI, a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life.